Book contents
- Practical Pathology of Serous Membranes
- Practical Pathology of Serous Membranes
- Copyright page
- Contents
- Contributors
- Preface
- 1 The Mesothelium
- 2 Classification of Neoplastic and Non-neoplastic Lesions of the Serosal Surfaces
- 3 Multi-modality Imaging of Pleural and Peritoneal Disease
- 4 Processing of Pleural and Peritoneal Pathologic Specimens for the Diagnosis of Malignant Mesothelioma
- 5 Cytology of Pleural and Peritoneal Lesions
- 6 Surgical Pathology of Non-neoplastic Conditions of the Pleura, Pericardium, and Peritoneum
- 7 Surgical Pathology of Benign Lesions of Mesothelial Origin
- 8 Epidemiology, Etiology, and Pathogenesis of Malignant Mesothelioma
- 9 Pathologic “Markers” of Above Background Asbestos Exposure
- 10 Molecular Aspects of Malignant Mesothelioma and Other Tumors of the Pleura and Peritoneum
- 11 Pathology of Malignant Mesothelioma
- 12 Surgical Treatment of Pleural and Peritoneal Mesothelioma
- 13 Non-surgical Treatment of Malignant Mesothelioma
- 14 Primary Carcinoma of the Pleura and Peritoneum
- 15 Lymphoid Malignancies of the Pleura and Peritoneum
- 16 Mesenchymal and Other Unusual Tumors of the Pleura and Peritoneum
- Index
- References
13 - Non-surgical Treatment of Malignant Mesothelioma
Published online by Cambridge University Press: 16 March 2018
Book contents
- Practical Pathology of Serous Membranes
- Practical Pathology of Serous Membranes
- Copyright page
- Contents
- Contributors
- Preface
- 1 The Mesothelium
- 2 Classification of Neoplastic and Non-neoplastic Lesions of the Serosal Surfaces
- 3 Multi-modality Imaging of Pleural and Peritoneal Disease
- 4 Processing of Pleural and Peritoneal Pathologic Specimens for the Diagnosis of Malignant Mesothelioma
- 5 Cytology of Pleural and Peritoneal Lesions
- 6 Surgical Pathology of Non-neoplastic Conditions of the Pleura, Pericardium, and Peritoneum
- 7 Surgical Pathology of Benign Lesions of Mesothelial Origin
- 8 Epidemiology, Etiology, and Pathogenesis of Malignant Mesothelioma
- 9 Pathologic “Markers” of Above Background Asbestos Exposure
- 10 Molecular Aspects of Malignant Mesothelioma and Other Tumors of the Pleura and Peritoneum
- 11 Pathology of Malignant Mesothelioma
- 12 Surgical Treatment of Pleural and Peritoneal Mesothelioma
- 13 Non-surgical Treatment of Malignant Mesothelioma
- 14 Primary Carcinoma of the Pleura and Peritoneum
- 15 Lymphoid Malignancies of the Pleura and Peritoneum
- 16 Mesenchymal and Other Unusual Tumors of the Pleura and Peritoneum
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Practical Pathology of Serous Membranes , pp. 183 - 189Publisher: Cambridge University PressPrint publication year: 2018
References
Aisner, J. Current approach to malignant mesothelioma of the pleura. Chest. 1995;107:332S.CrossRefGoogle ScholarPubMed
Berghmans, T, Paesmans, M, Lalami, Y, Louviaux, I, Luce, S, Mascaux, C, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer. 2002;38:111.CrossRefGoogle ScholarPubMed
Tomek, S, Emri, S, Krejcy, K, Manegold, C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer. 2003;88:167.CrossRefGoogle ScholarPubMed
Byrne, MJ, Nowak, AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257–60.CrossRefGoogle ScholarPubMed
Vogelzang, NJ, Rusthoven, JJ, Symanowski, J, Denham, C, Kaukel, E, Ruffie, P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.CrossRefGoogle ScholarPubMed
van Meerbeeck, JP, Gaafar, R, Manegold, C, Van Klaveren, RJ, Van Marck, EA, Vincent, M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–89.CrossRefGoogle ScholarPubMed
Symanowski, JT, Rusthoven, J, Nguyen, B, et al. Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma (abstract). Proc Am Soc Clin Oncol 2003;22:647a.Google Scholar
Curran, D, Sahmoud, T, Therasse, P, van Meerbeeck, J, Postmus, PE, Giaccone, G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145–52.CrossRefGoogle ScholarPubMed
Gralla, RJ, Hollen, PJ, Liepa, AM, et al. Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs cisplatin trial using the LCSS-meso instrument (abstract). Proc Am Soc Clin Oncol. 2003;22:621a.Google Scholar
Woods, B, Paracha, N, Scott, DA, Thatcher, N. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. Lung Cancer. 2012;75:261–67.CrossRefGoogle ScholarPubMed
Ceresoli, GL, Castagneto, B, Zucali, PA, Favoretto, A, Mencoboni, M, Grossi, F, et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer. 2008;99:51–56.CrossRefGoogle ScholarPubMed
Katirtzoglou, N, Gkiozos, I, Makrilia, N, Tsaroucha, E, Rapti, A, Stratakos, G, et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer. 2010;11:30–35.Google Scholar
Santoro, A, O'Brien, ME, Stahel, RA, Nackaerts, K, Baas, P, Karthaus, M, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3:756–63.CrossRefGoogle ScholarPubMed
O'Brien, ME, Watkins, D, Ryan, C, Priest, K, Corbishley, C, Norton, A, et al. A randomized trial in malignant mesothelioma of early versus delayed chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol. 2006;17:270–75.CrossRefGoogle Scholar
Janne, PA, Simon, GR, Langer, CJ, Taub, RN, Dowlati, A, Fidias, P, et al. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol. 2008;26:1465–71.CrossRefGoogle ScholarPubMed
Galetta, D, Catino, A, Misino, A, Logroscino, A, Fico, M. Sarcomatoid mesothelioma: future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcome disease. Tumori. 2016;102(2):127–30.Google Scholar
Gattoni, E, Grosso, F, Roveta, A, Libener, R, Degiovanni, D, Mancuso, M, et al. Outcomes of sarcomatoid malignant pleural mesothelioma, a distinct clinical entity. ASCO Meeting Abstracts. 2012;30:7084.Google Scholar
Mansfield, AS, Symanowski, JT, Peikert, T. Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. Lung Cancer. 2014;86(2):133–36.Google Scholar
Byrne, MJ, Davidson, JA, Musk, AW, Dewar, J, van Hazel, G, Buck, M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17:25–30.CrossRefGoogle ScholarPubMed
Nowak, AK, Byrne, MJ, Williamson, R, Ryan, G, Segal, A, Fielding, D, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87:491–96.CrossRefGoogle ScholarPubMed
Chahinian, AP, Antman, K, Goutsou, M, Corson, JM, Suzuki, Y, Modeas, C, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol. 1993;11:1559.Google Scholar
Henss, H, Fiebig, HH, Schildge, J, Arnold, H, Hasse, J. Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie. 1988;11:118.Google ScholarPubMed
Ciuleanu, T, Brodowicz, T, Zielinski, C, Kim, JH, Krzakowski, M, Laack, E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432–40.CrossRefGoogle ScholarPubMed
Jassem, J, Ramlau, R, Santoro, A, Schuette, W, Chemaissani, A, Hong, S, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26:1698–704.Google Scholar
Zauderer, MG, Kass, SL, Woo, K, Sima, CS, Ginsberg, MS, Krug, LM, et al. Vinorelbine and gemcitabine as second-line or third-line therapy for malignant pleural mesothelioma. Lung Cancer. 2014;84:271–74.Google Scholar
Kindler, HL, Karrison, TG, Gandara, DR, Lu, C, Krug, LM, Stevenson, JP, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012;30:2509–15.Google Scholar
Dowell, JE, Dunphy, FR, Taub, RN, Gerber, DE, Ngov, L, Yan, J, et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012;77(3):567–71.CrossRefGoogle ScholarPubMed
Zalcman, G, et al. Bevacizumab 25mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCTGFPC-0701 MAPS randomizes phase 3 trial. ASCO Meeting Abstracts. 2015;400s:7500.Google Scholar
Jahan, T, Gu, L, Kratzke, R, Dudek, A, Otterson, GA, Wang, X, et al. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012;76:393–96.CrossRefGoogle Scholar
Garland, LL, Chansky, K, Wozniak, AJ, Tsao, AS, Gadgel, SM, Veerschraegen, CF, et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol. 2011;6:1938–45.Google Scholar
Campbell, NP, Kunnavakkam, R, Leighl, NB, et al. Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of The University of Chicago Phase II Consortium. ASCO Meeting Abstracts. 2011;29:7027.Google Scholar
Curnis, F, Arrigoni, G, Sacchi, A, Fischetti, L, Arap, W, Pasqualini, R, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 2002;62:867–74.Google Scholar
Rossoni, G, Gregorc, V, Vigano, MG, Butta, A, Ghio, D, Lambiase, A, et al. NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM). ASCO Meeting Abstracts. 2012;30:7076.Google Scholar
Gaafar, RM, Favoretto, A, Gregorc, V, Grossi, F, Jassem, J, Polychronis, A, et al. Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM). ASCO Meeting Abstracts. 2015;400s:7501.Google Scholar
Hassan, R, Sharon, E, Thomas, A, Zhang, J, Ling, A, Miettinen, M, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor and cancer antigen 125. Cancer. 2014;120(21):3311–19.Google Scholar
Hassan, R, Jahan, TM, Kindler, HL, Bazhenova, L, Reck, M, Thomas, A, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927–36.CrossRefGoogle ScholarPubMed
Stevenson, J, Kindler, HL, Schwed, D, et al. Phase II trial of anti-transforming growth factor-beta (TGFβ) monoclonal antibody GC1008 in relapsed malignant pleural mesothelioma (MPM). ASCO Meeting Abstracts. 2012;30:7077.Google Scholar
Filiberti, R, Marroni, P, Neri, M, Ardizzoni, A, Betta, PG, Cafferata, MA, et al. Serum PDGF-AB in pleural mesothelioma. Tumour Biol. 2005;26:221–26.CrossRefGoogle ScholarPubMed
Garland, LL, Rankin, C, Gandara, DR, Rivkin, SE, Scott, KM, Nagle, RB, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007;25:2406–13.CrossRefGoogle ScholarPubMed
Govindan, R, Kratzke, RA, Herndon, JE, 2nd, Niehans, GA, Vollmer, R, Watson, D, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005;11:2300–04.CrossRefGoogle ScholarPubMed
Laurie, SA, Gupta, A, Chu, Q, Lee, CW, Morzycki, W, Feld, R, et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group. J Thorac Oncol. 2011;6:1950–54.Google Scholar
Dubey, S, Janne, PA, Krug, L, Pang, H, Wang, X, Heinze, R, et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010;5:1655–61.Google Scholar
Dudek, AZ, Pang, H, Kratzke, RA, Otterson, GA, Hodgson, L, Vokes, EE, et al. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012;7:755–59.Google Scholar
Reck, M, Krzakowski, M, Jassem, J, et al. Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM). ASCO Meeting Abstracts. 2009;27:7507.Google Scholar
Garland, LL, Ou, S-H, Moon, J, Mack, PC, Testa, J, Tsao, AS, et al. SWOG 0722: a phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015;10(2):387–91.Google Scholar
O'Brien, M, Gaafar, RM, Popat, S, Grossi, F, Price, A, Talbot, DC, et al. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). Eur J Cancer. 2013;49(13):2815–22.Google ScholarPubMed